According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
A number of other equities analysts have also weighed in on the stock. HC Wainwright decreased their price objective on shares of Adamas Pharmaceuticals from $40.00 to $30.00 and set a buy rating for the company in a report on Tuesday, May 28th. Mizuho restated a sell rating and issued a $5.00 price objective on shares of Adamas Pharmaceuticals in a report on Wednesday, April 24th. ValuEngine upgraded shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, August 1st. Cowen set a $5.00 price objective on shares of Adamas Pharmaceuticals and gave the stock a hold rating in a report on Friday, August 9th. Finally, Evercore ISI restated a buy rating and issued a $55.00 price objective on shares of Adamas Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $21.81.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.08. Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 149.97%. The company had revenue of $12.69 million during the quarter, compared to analyst estimates of $12.62 million. On average, sell-side analysts forecast that Adamas Pharmaceuticals will post -3.74 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Alps Advisors Inc. raised its stake in Adamas Pharmaceuticals by 4.5% during the 1st quarter. Alps Advisors Inc. now owns 66,026 shares of the specialty pharmaceutical company’s stock valued at $469,000 after buying an additional 2,860 shares during the last quarter. BlackRock Inc. raised its stake in Adamas Pharmaceuticals by 9.3% during the 4th quarter. BlackRock Inc. now owns 2,064,758 shares of the specialty pharmaceutical company’s stock valued at $17,633,000 after buying an additional 174,844 shares during the last quarter. Bingham Osborn & Scarborough LLC raised its stake in Adamas Pharmaceuticals by 8.8% during the 1st quarter. Bingham Osborn & Scarborough LLC now owns 145,913 shares of the specialty pharmaceutical company’s stock valued at $1,037,000 after buying an additional 11,805 shares during the last quarter. Deutsche Bank AG raised its stake in Adamas Pharmaceuticals by 506.7% during the 4th quarter. Deutsche Bank AG now owns 274,050 shares of the specialty pharmaceutical company’s stock valued at $2,339,000 after buying an additional 228,883 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Adamas Pharmaceuticals by 37.5% during the 1st quarter. SG Americas Securities LLC now owns 33,766 shares of the specialty pharmaceutical company’s stock valued at $240,000 after buying an additional 9,213 shares during the last quarter. Institutional investors and hedge funds own 76.49% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Featured Article: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.